CN107496510B - Cyclocarya paliurus capsule and preparation method thereof - Google Patents
Cyclocarya paliurus capsule and preparation method thereof Download PDFInfo
- Publication number
- CN107496510B CN107496510B CN201710802725.6A CN201710802725A CN107496510B CN 107496510 B CN107496510 B CN 107496510B CN 201710802725 A CN201710802725 A CN 201710802725A CN 107496510 B CN107496510 B CN 107496510B
- Authority
- CN
- China
- Prior art keywords
- cyclocarya paliurus
- parts
- raw material
- extract
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000233779 Cyclocarya paliurus Species 0.000 title claims abstract description 137
- 239000002775 capsule Substances 0.000 title claims abstract description 114
- 238000002360 preparation method Methods 0.000 title abstract description 31
- 239000000284 extract Substances 0.000 claims abstract description 115
- 239000002994 raw material Substances 0.000 claims abstract description 108
- 239000000945 filler Substances 0.000 claims abstract description 55
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 25
- 240000000249 Morus alba Species 0.000 claims abstract description 25
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 25
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 25
- 229960005375 lutein Drugs 0.000 claims abstract description 24
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 24
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 24
- 108010010803 Gelatin Proteins 0.000 claims abstract description 23
- 229920000159 gelatin Polymers 0.000 claims abstract description 23
- 239000008273 gelatin Substances 0.000 claims abstract description 23
- 235000019322 gelatine Nutrition 0.000 claims abstract description 23
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 23
- 239000001656 lutein Substances 0.000 claims abstract description 23
- 235000012680 lutein Nutrition 0.000 claims abstract description 23
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 23
- 229920002261 Corn starch Polymers 0.000 claims abstract description 22
- 239000008120 corn starch Substances 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 claims abstract description 12
- 229920001277 pectin Polymers 0.000 claims abstract description 7
- 235000010987 pectin Nutrition 0.000 claims abstract description 7
- 239000001814 pectin Substances 0.000 claims abstract description 7
- 244000078912 Trichosanthes cucumerina Species 0.000 claims abstract 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 30
- 229920002472 Starch Polymers 0.000 claims description 15
- SRBFZHDQGSBBOR-QMKXCQHVSA-N alpha-L-arabinopyranose Chemical compound O[C@H]1CO[C@@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-QMKXCQHVSA-N 0.000 claims description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 239000008107 starch Substances 0.000 claims description 15
- 235000019698 starch Nutrition 0.000 claims description 15
- 244000269722 Thea sinensis Species 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 35
- 210000004369 blood Anatomy 0.000 abstract description 35
- 238000002156 mixing Methods 0.000 abstract description 25
- 230000001603 reducing effect Effects 0.000 abstract description 21
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 3
- 238000012545 processing Methods 0.000 abstract description 3
- 239000002671 adjuvant Substances 0.000 abstract description 2
- 244000302512 Momordica charantia Species 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- 239000000463 material Substances 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 10
- 235000018365 Momordica dioica Nutrition 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000233778 Cyclocarya Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 244000070299 Hydrangea aspera Species 0.000 description 1
- 235000002784 Hydrangea aspera Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 244000020191 Salix babylonica Species 0.000 description 1
- 235000002493 Salix babylonica Nutrition 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241000322029 Senna nomame Species 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 241001113787 Strychnos Species 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 229930185803 charantin Natural products 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000020344 instant tea Nutrition 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- -1 momordin Natural products 0.000 description 1
- 239000009562 momordin Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229930002600 steroidal saponin Natural products 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of cyclocarya paliurus deep processing, and provides cyclocarya paliurus capsules and a preparation method thereof. The cyclocarya paliurus capsule comprises a filler and a capsule shell, wherein the filler is prepared from a first raw material, the capsule shell is prepared from a second raw material, and the first raw material comprises: cyclocarya paliurus extract, bitter gourd extract, mulberry leaf extract and lutein; the second raw material comprises corn starch, pectin and gelatin. The cyclocarya paliurus capsule is convenient to carry and eat, and has an excellent blood sugar reducing effect. The preparation method of the cyclocarya paliurus capsule comprises the following steps: mixing the first raw material with medicinal adjuvants, granulating to obtain filler, mixing the second raw material with water to obtain capsule shell, and filling the filler into capsule. The preparation method is simple and reasonable in technology, and can be used for industrial large-scale production, and the obtained cyclocarya paliurus capsules have an excellent blood sugar reducing effect.
Description
Technical Field
The invention relates to the technical field of cyclocarya paliurus deep processing, and particularly relates to cyclocarya paliurus capsules and a preparation method thereof.
Background
Cyclocarya paliurus (Batal.) Ill., Cassia nomame, Strychnos, Salix babylonica, and hydrangea aspera (sweet tea tree) is a plant belonging to cyclocarya of Juglandaceae of the class Dicotyledoneae. The tree shape is like willow, the fruits are like copper cash and green, and the tree is drooping and swaying in the wind. Cyclocarya paliurus is a wiggery tree species in the glacier century, is a unique single species plant in China, and is a tall deciduous tree which can survive in broad-leaved forests in shady and humid areas with the altitude of 500-2500 m. According to records of Chinese traditional medicine resource, the tender leaves are sweet and moist, and have various functions beneficial to human health, such as promoting the production of body fluid to quench thirst, clearing away heat and toxic materials, treating stubborn dermatitis and the like. Cyclocarya paliurus is a precious tree species which integrates various values of medicine, material, garden appreciation and the like.
Because the development time of cyclocarya paliurus in China is short, and because of some characteristics of cyclocarya paliurus, certain difficulty exists in further deep development and comprehensive utilization, the development and utilization of cyclocarya paliurus reported in the prior art are mostly concentrated on extracting active substances of cyclocarya paliurus, but the deep processing and utilization of cyclocarya paliurus are less. At present, cyclocarya paliurus is mostly cyclocarya paliurus health-care tea, cyclocarya paliurus instant tea, cyclocarya paliurus buccal tablets and the like, but the products have the defects of low content of effective components, poor stability, low bioavailability and the like, so that the efficacy of the cyclocarya paliurus is limited.
Therefore, the invention of a cyclocarya paliurus product capable of solving the problems becomes a problem to be solved at present.
Disclosure of Invention
The invention aims to provide a cyclocarya paliurus capsule which is convenient to carry and eat and has an excellent blood sugar reducing effect.
The second purpose of the invention is to provide a preparation method of cyclocarya paliurus capsules, the preparation method is simple and reasonable in technology and can be used for industrial large-scale production, and the obtained cyclocarya paliurus capsules have excellent blood sugar reducing efficacy.
The technical problem to be solved by the invention is realized by adopting the following technical scheme.
A cyclocarya paliurus capsule comprises a filler and a capsule shell, wherein the filler is prepared from a first raw material, the capsule shell is prepared from a second raw material, and the first raw material comprises cyclocarya paliurus extract, balsam pear extract, mulberry leaf extract and lutein; the second raw material comprises corn starch, pectin and gelatin; the health-care tea comprises, by weight, 30-50 parts of cyclocarya paliurus extract, 10-15 parts of bitter gourd extract, 12-18 parts of mulberry leaf extract, 2-3 parts of lutein, 1-2 parts of corn starch, 1-1.8 parts of pectin sugar and 1-1.5 parts of gelatin.
A preparation method of the cyclocarya paliurus capsule comprises the following steps: mixing the first raw material with medicinal adjuvants, granulating to obtain filler, mixing the second raw material with water to obtain capsule shell, and filling the filler into capsule.
The cyclocarya paliurus capsule and the preparation method thereof provided by the invention have the beneficial effects that:
the cyclocarya paliurus extract contains a plurality of substances, and cyclocarya paliurus polysaccharide has a good blood sugar reducing effect and can effectively improve the glucose tolerance of a patient with hyperglycemia; meanwhile, cyclocarya paliurus glycoside in the cyclocarya paliurus extract is a natural sweetener and is non-caloric saponins, so that the requirement of a patient with hyperglycemia on sweetness can be met, the condition is not aggravated, and the cyclocarya paliurus extract has good effects of reducing blood sugar, blood fat and blood pressure;
the raw materials are matched with each other to exert curative effect synergistically, and have the effect of obviously reducing blood sugar. Secondly, the raw materials of the capsule are all natural medicinal plants without side effect, and do not generate dependence on the diabetic patients.
The preparation method of the cyclocarya paliurus extract is characterized in that the first raw material and medicinal auxiliary materials are mixed and granulated to prepare a filler, the second raw material and water are mixed to prepare a capsule shell, and the filler is filled into the capsule.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
The cyclocarya paliurus capsule and the preparation method thereof according to the embodiment of the invention are specifically described below.
The invention provides a cyclocarya paliurus capsule, which comprises a filler and a capsule shell, wherein the filler is prepared from a first raw material, the capsule shell is prepared from a second raw material, and the first raw material comprises the following components in parts by weight: 30-50 parts of cyclocarya paliurus extract, 10-15 parts of bitter gourd extract, 12-18 parts of mulberry leaf extract and 2-3 parts of lutein, wherein the second raw material comprises 1-2 parts of corn starch, 1-1.8 parts of pectin sugar and 1-1.5 parts of gelatin.
The selection and the proportion of the raw material components are scientifically designed, so that the raw materials are matched with each other to play a role in synergy, and by adopting the proportion, the active ingredients of the raw materials interact and supplement with each other, and the prepared cyclocarya paliurus capsule has an excellent blood sugar reducing effect.
Preferably, in order to further enhance the blood sugar reducing capability of the cyclocarya paliurus capsule, the cyclocarya paliurus capsule comprises 35-45 parts by weight of cyclocarya paliurus extract, 11-14 parts by weight of bitter gourd extract, 13-17 parts by weight of mulberry leaf extract, 2.2-2.8 parts by weight of lutein, 1.2-1.8 parts by weight of corn starch, 1.2-1.6 parts by weight of pectin and 1.2-1.4 parts by weight of gelatin; within this range, most preferably, the weight parts of cyclocarya paliurus extract are 40 parts, the weight parts of balsam pear extract are 12 parts, the weight parts of mulberry leaf extract are 15 parts, the weight parts of lutein are 2.5 parts, the weight parts of corn starch are 1.6 parts, the weight parts of pectin sugar are 1.4 parts, and the weight parts of gelatin are 1.3 parts.
The filler is made from a first material comprising: cyclocarya paliurus extract, bitter gourd extract, mulberry leaf extract and lutein.
Wherein the cyclocarya paliurus extract preferably comprises cyclocarya paliurus leaf extract and cyclocarya paliurus root extract; cyclocarya paliurus leaves and cyclocarya paliurus roots are different medicinal parts of cyclocarya paliurus and have the functions of reducing blood sugar and improving body immunity. The content ratio of the medicinal effective components of the two components is different, and the combined application can improve the whole curative effect. Wherein the cyclocarya paliurus leaves have the effects of clearing heat and quenching thirst; cyclocarya paliurus root has effects of diminishing inflammation, relieving pain and dispelling pathogenic wind.
In the embodiment, the weight ratio of the cyclocarya paliurus leaf extract to the cyclocarya paliurus root extract is preferably 1.2-2: 1-1.8, and the cyclocarya paliurus extract has better blood sugar reducing effect and the function of improving the immunity of the organism within the mixture ratio range.
The extract of Momordica charantia contains steroidal saponins such as momordin, insulinoids and alkaloids, which impart hypoglycemic activity to Momordica charantia. Charantin stimulates the release of insulin and hinders the formation of glucose in the blood stream, a function which may play a great role in the treatment of diabetes, particularly non-insulin dependent diabetes mellitus.
The hypoglycemic effect of the mulberry leaf extract is realized by two ways: the alkaloid has an inhibiting effect on the activity of disaccharide clastic enzyme, so that the absorption of the disaccharide by small intestine is inhibited, and the high peak value of blood sugar after eating is reduced; secondly, the mulberry leaf alkaloid and mulberry leaf polysaccharide promote beta cell insulin, and the insulin can promote the utilization of sugar by cells, the synthesis of hepatic glycogen and the improvement of glycometabolism, and finally achieve the effect of reducing blood sugar.
Xanthophyll is an excellent antioxidant, and can prevent cell and organ damage caused by free radicals in human body, thereby preventing cardiovascular sclerosis, coronary heart disease, tumor, etc. caused by aging of organism. Lutein and zeaxanthin are the only 2 kinds of carotenes in the eye, and the prevention of vision loss and blindness caused by macular degeneration in the aged eyeball is the unique function of lutein.
In this embodiment, the dosage forms of the cyclocarya paliurus extract, the momordica charantia extract, and the mori folium extract are not particularly limited, and preferably, dry extracts of aqueous extracts are used in view of convenience in preparing capsule fillings and reduction in production costs.
In the embodiment of the present invention, preferably, the first raw material further includes pharmaceutical excipients, and the pharmaceutical excipients include a binder, a wetting agent, and a disintegrant; the binder is beneficial to the combination of all raw material components and the filling of the capsule; wetting the feedstock by reducing the surface tension or interfacial tension of the feedstock such that water can spread over or penetrate the surface of the feedstock; the disintegrating agent can rapidly dissolve and absorb the functional components of the medicine, plays a role, and has good water absorption and expansibility, thereby realizing the disintegration of the capsule.
Preferably, in this embodiment, the binder comprises starch, which can function as an adhesive between the raw materials; the wetting agent comprises magnesium stearate which has lubricating, anti-sticking and glidant effects and is mainly used as a lubricant, a glidant, an anti-sticking agent and the like of tablets, capsules and the like in the medicament. In the embodiment, the weight ratio of the starch to the magnesium stearate is preferably 40-50: 1, and the filler has excellent binding and wetting capabilities within the mixing ratio range.
The capsule shell is made from a second raw material which comprises corn starch, pectin and gelatin. The corn starch, the pectin sugar and the gelatin are matched with each other in a reasonable proportion so as to solve the problem of drug resistance caused by the adoption of single gelatin in the traditional preparation of capsules.
The embodiment of the invention also provides a preparation method of the cyclocarya paliurus capsule, which comprises the following steps: the first raw material and the pharmaceutical excipients are mixed and granulated to prepare the filler, preferably, the relative density of the first raw material is 1.2-1.8, the filler can be better filled into the capsule shell within the relative density range, then the second raw material is mixed with water to prepare the capsule shell, and the filler is filled into the capsule.
The features and properties of the present invention are described in further detail below with reference to examples.
Example 1
The embodiment of the invention provides a cyclocarya paliurus capsule, which comprises a filler and a capsule shell, wherein the filler is made of a first raw material, and the capsule shell is made of a second raw material.
The first raw material comprises the following components in parts by weight: 30 parts of cyclocarya paliurus extract (the weight ratio of the cyclocarya paliurus leaf extract to the cyclocarya paliurus root extract is 1.2:1), 10 parts of bitter gourd extract, 12 parts of mulberry leaf extract, 2 parts of lutein, 40 parts of starch and 1 part of magnesium stearate; the second raw material comprises: 1 part of corn starch, 1 part of pectin sugar and 1 part of gelatin.
The embodiment provides a preparation method of cyclocarya paliurus capsules, which comprises the following steps: mixing the first raw material and pharmaceutic adjuvant, granulating to prepare a filler, mixing the second raw material with water to prepare a capsule shell, and filling the filler into the capsule shell, wherein the relative density of the first raw material is 1.2-1.8.
Example 2
The embodiment provides a cyclocarya paliurus capsule, which comprises a filling material and a capsule shell, wherein the filling material is made of a first raw material, and the capsule shell is made of a second raw material.
The first raw material comprises the following components in parts by weight: 50 parts of cyclocarya paliurus extract (the weight ratio of the cyclocarya paliurus leaf extract to the cyclocarya paliurus root extract is 1.2:1), 15 parts of balsam pear extract, 18 parts of mulberry leaf extract, 3 parts of lutein, 50 parts of starch and 1 part of magnesium stearate; the second raw material comprises: 2 parts of corn starch, 1.8 parts of pectin sugar and 1.5 parts of gelatin.
The embodiment provides a preparation method of cyclocarya paliurus capsules, which comprises the following steps: mixing the first raw material and pharmaceutic adjuvant, granulating to prepare a filler, mixing the second raw material with water to prepare a capsule shell, and filling the filler into the capsule shell, wherein the relative density of the first raw material is 1.2-1.8.
Example 3
The embodiment of the invention provides a cyclocarya paliurus capsule, which comprises a filler and a capsule shell, wherein the filler is made of a first raw material, and the capsule shell is made of a second raw material.
The first raw material comprises the following components in parts by weight: 35 parts of cyclocarya paliurus extract (the weight ratio of the cyclocarya paliurus leaf extract to the cyclocarya paliurus root extract is 1.2:1), 11 parts of balsam pear extract, 13 parts of mulberry leaf extract, 2.2 parts of lutein, 45 parts of starch and 1 part of magnesium stearate; the second raw material comprises: 1.2 parts of corn starch, 1.2 parts of pectin sugar and 1.2 parts of gelatin.
The embodiment provides a preparation method of cyclocarya paliurus capsules, which comprises the following steps: mixing the first raw material and pharmaceutic adjuvant, granulating to prepare a filler, mixing the second raw material with water to prepare a capsule shell, and filling the filler into the capsule shell, wherein the relative density of the first raw material is 1.2-1.8.
Example 4
The embodiment provides a cyclocarya paliurus capsule, which comprises a filling material and a capsule shell, wherein the filling material is made of a first raw material, and the capsule shell is made of a second raw material.
The first raw material comprises the following components in parts by weight: 45 parts of cyclocarya paliurus extract (the weight ratio of the cyclocarya paliurus leaf extract to the cyclocarya paliurus root extract is 1.2:1), 14 parts of balsam pear extract, 17 parts of mulberry leaf extract, 2.8 parts of lutein, 45 parts of starch and 1 part of magnesium stearate; the second raw material comprises: 1.8 parts of corn starch, 1.6 parts of pectin sugar and 1.4 parts of gelatin.
The embodiment provides a preparation method of cyclocarya paliurus capsules, which comprises the following steps: mixing the first raw material and pharmaceutic adjuvant, granulating to prepare a filler, mixing the second raw material with water to prepare a capsule shell, and filling the filler into the capsule shell, wherein the relative density of the first raw material is 1.2-1.8.
Example 5
The embodiment provides a cyclocarya paliurus capsule, which comprises a filling material and a capsule shell, wherein the filling material is made of a first raw material, and the capsule shell is made of a second raw material.
The first raw material comprises the following components in parts by weight: 40 parts of cyclocarya paliurus extract (the weight ratio of the cyclocarya paliurus leaf extract to the cyclocarya paliurus root extract is 1.2:1), 12 parts of balsam pear extract, 15 parts of mulberry leaf extract, 2.5 parts of lutein, 45 parts of starch and 1 part of magnesium stearate; the second raw material comprises: 1.6 parts of corn starch, 1.4 parts of pectin sugar and 1.3 parts of gelatin.
The embodiment provides a preparation method of cyclocarya paliurus capsules, which comprises the following steps: mixing the first raw material and pharmaceutic adjuvant, granulating to prepare a filler, mixing the second raw material with water to prepare a capsule shell, and filling the filler into the capsule shell, wherein the relative density of the first raw material is 1.2-1.8.
Example 6
The embodiment provides a cyclocarya paliurus capsule, which comprises a filling material and a capsule shell, wherein the filling material is made of a first raw material, and the capsule shell is made of a second raw material.
The first raw material comprises the following components in parts by weight: 40 parts of cyclocarya paliurus extract (the weight ratio of the cyclocarya paliurus leaf extract to the cyclocarya paliurus root extract is 2:1.8), 12 parts of balsam pear extract, 15 parts of mulberry leaf extract, 2.5 parts of lutein, 45 parts of starch and 1 part of magnesium stearate; the second raw material comprises: 1.5 parts of corn starch, 1.5 parts of pectin sugar and 1.2 parts of gelatin.
The embodiment provides a preparation method of cyclocarya paliurus capsules, which comprises the following steps: mixing the first raw material and pharmaceutic adjuvant, granulating to prepare a filler, mixing the second raw material with water to prepare a capsule shell, and filling the filler into the capsule shell, wherein the relative density of the first raw material is 1.2-1.8.
Example 7
The embodiment provides a cyclocarya paliurus capsule, which comprises a filling material and a capsule shell, wherein the filling material is made of a first raw material, and the capsule shell is made of a second raw material.
The first raw material comprises the following components in parts by weight: 40 parts of cyclocarya paliurus extract (the weight ratio of the cyclocarya paliurus leaf extract to the cyclocarya paliurus root extract is 1.5:1.6), 12 parts of balsam pear extract, 15 parts of mulberry leaf extract, 2.5 parts of lutein, 45 parts of starch and 1 part of magnesium stearate; the second raw material comprises: 1.5 parts of corn starch, 1.5 parts of pectin sugar and 1.2 parts of gelatin.
The embodiment provides a preparation method of cyclocarya paliurus capsules, which comprises the following steps: mixing the first raw material and pharmaceutic adjuvant, granulating to prepare a filler, mixing the second raw material with water to prepare a capsule shell, and filling the filler into the capsule shell, wherein the relative density of the first raw material is 1.2-1.8.
Comparative example 1
The comparison example provides a cyclocarya paliurus capsule, which comprises a filler and a capsule shell, wherein the filler is made of a first raw material, and the capsule shell is made of a second raw material.
The first raw material comprises the following components in parts by weight: 20 parts of cyclocarya paliurus extract (the weight ratio of the cyclocarya paliurus leaf extract to the cyclocarya paliurus root extract is 1.2:1), 20 parts of bitter gourd extract, 20 parts of mulberry leaf extract, 5 parts of lutein, 10 parts of starch and 5 parts of magnesium stearate; the second raw material comprises: 3 parts of corn starch, 2 parts of pectin sugar and 0.5 part of gelatin.
The comparative example provides a preparation method of cyclocarya paliurus capsules, which comprises the following steps: mixing the first raw material and pharmaceutic adjuvant, granulating to prepare a filler, mixing the second raw material with water to prepare a capsule shell, and filling the filler into the capsule shell, wherein the relative density of the first raw material is 1.2-1.8.
Comparative example 2
The comparison example provides a cyclocarya paliurus capsule, which comprises a filler and a capsule shell, wherein the filler is made of a first raw material, and the capsule shell is made of a second raw material.
The first raw material comprises the following components in parts by weight: 30 parts of cyclocarya paliurus extract (the weight ratio of the cyclocarya paliurus leaf extract to the cyclocarya paliurus root extract is 0.5:2), 10 parts of bitter gourd extract, 12 parts of mulberry leaf extract, 2 parts of lutein, 40 parts of starch and 1 part of magnesium stearate; the second raw material comprises: 1 part of corn starch, 1 part of pectin sugar and 1 part of gelatin.
The comparative example provides a preparation method of cyclocarya paliurus capsules, which comprises the following steps: mixing the first raw material and pharmaceutic adjuvant, granulating to prepare a filler, mixing the second raw material with water to prepare a capsule shell, and filling the filler into the capsule shell, wherein the relative density of the first raw material is 1.2-1.8.
Comparative example 3
The comparison example provides a cyclocarya paliurus capsule, which comprises a filler and a capsule shell, wherein the filler is made of a first raw material, and the capsule shell is made of a second raw material.
The first raw material comprises the following components in parts by weight: 30 parts of cyclocarya paliurus extract (the weight ratio of the cyclocarya paliurus leaf extract to the cyclocarya paliurus root extract is 1.2:1), 10 parts of bitter gourd extract, 12 parts of mulberry leaf extract, 2 parts of lutein, 40 parts of starch and 1 part of magnesium stearate; the second raw material comprises: 1 part of corn starch, 1 part of pectin sugar and 1 part of gelatin.
The comparative example provides a preparation method of cyclocarya paliurus capsules, which comprises the following steps: mixing the first raw material and pharmaceutic adjuvant, granulating to prepare a filler, mixing the second raw material with water to prepare a capsule shell, and filling the filler into the capsule shell, wherein the relative density of the first raw material is 2-3.
Test examples
Experiments and results of blood sugar lowering tests.
Subject: selecting 120 healthy mice with similar sizes, wherein the male and female halves of the mice are divided into 12 groups, each group comprises 10 mice, and the male and female halves of the mice are set as experimental groups 1-12;
the experimental steps are as follows: mice of experimental groups 1-12 were fasted for 24h before the experiment, except experimental group 12, mice of experimental groups 1-11 were injected with 200mg/kg streptozotocin 10ml/kg via tail vein, and blood glucose concentration and body weight were measured after 48 h. Detecting that the mice with the blood sugar concentration of 15-30 mmol/L are successfully modeled (the fasting blood sugar reference value of normal mice is 3.5-7.1 mmol/L);
preparing the fillers of the cyclocarya paliurus capsules provided in examples 1-7 and comparative examples 1-3 and distilled water into 2g/kg of experimental medicines, wherein the experimental medicines are respectively set to be 1-10;
for mice of experimental groups 1-10: the mice are respectively administrated with 10ml/kg of experimental drug for 1-10 times per day for intragastric administration, 1 time per day and 21 days of continuous drug administration. During the experiment, water is freely drunk, and common feed is given;
for mice of experimental groups 11 and 12: mice were dosed daily with equal drug volumes of distilled water for intragastric administration. During the experiment, water was freely drunk and ordinary feed was given.
And (3) blood sugar test: the ACCU-CHEK Advantage blood sugar detection system measures the blood sugar of the tested mouse; the total cholesterol of the test mice was measured by AU2700 full-automatic biochemical analyzer, and the results are shown in table 1 below.
TABLE 1 influence of cyclocarya paliurus capsule filler on mouse body weight and blood glucose values
As can be seen from the data in Table 1, the blood sugar values and cholesterol values of the tested mice of the experimental groups 1-10 are obviously reduced compared with those of the tested mice of the experimental group 11, which indicates that the cyclocarya paliurus capsule filler prepared by the method has good blood sugar and cholesterol reducing effects.
The blood glucose and cholesterol values of the test mice of experimental groups 1-5 were significantly lower than those of the test mice of experimental group 8, and the best results were obtained with experimental group 5. The experimental groups 1 to 5 are the same as the experimental group 8 in preparation raw materials of the cyclocarya paliurus capsule, the preparation steps are the same, which shows that the cyclocarya paliurus extract, the balsam pear extract, the mulberry leaf extract, the lutein, the corn starch, the pectin, the gelatin, the proportion of the binder and the wetting agent have a great influence on the blood sugar reducing effect of the prepared filler, and the blood sugar reducing effect is better when the cyclocarya paliurus extract is 40 parts, the balsam pear extract is 12 parts, the mulberry leaf extract is 15 parts, the lutein is 2.5 parts, the corn starch is 1.6 parts, the pectin is 1.4 parts, the gelatin is 1.3 parts, the starch is 45 parts, and the magnesium stearate is 1 part in parts by weight.
The blood glucose and cholesterol values of the test mice of experimental groups 5-7 were significantly lower than those of the test mice of experimental group 9, and the best results were obtained with experimental group 7. The preparation raw materials and the proportion of the cyclocarya paliurus capsules of the experimental groups 5-7 are the same as those of the experimental group 9, the preparation steps are the same, the weight ratio range of the cyclocarya paliurus leaf extract and the cyclocarya paliurus root extract is shown, the cyclocarya paliurus leaf extract and the cyclocarya paliurus root extract have a large influence on the blood sugar reducing effect of the prepared filler, and the blood sugar reducing effect is better when the weight ratio of the cyclocarya paliurus leaf extract to the cyclocarya paliurus root extract is 1.2-2: 1-1.8 in parts.
The blood sugar value and the cholesterol value of the tested mouse of the experimental group 10 are higher than those of the tested mouse of the experimental group 1, the preparation raw materials and the proportion of the cyclocarya paliurus capsules of the tested mice of the experimental group 10 and the experimental group 1 are the same, the preparation steps are the same, and the blood sugar reducing effect of the prepared filler is the best when the relative density of the first raw material is 1.2-1.8.
In conclusion, the cyclocarya paliurus capsule provided by the embodiment of the invention is convenient to carry and eat, and has an excellent blood sugar reducing effect; the preparation method of the cyclocarya paliurus capsule provided by the embodiment of the invention is simple and reasonable in technology, and can be used for industrial large-scale production, and the obtained cyclocarya paliurus capsule has an excellent blood sugar reducing effect.
The embodiments described above are some, but not all embodiments of the invention. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Claims (1)
1. The cyclocarya paliurus capsule is characterized by comprising a filler and a capsule shell, wherein the filler is prepared from a first raw material, the capsule shell is prepared from a second raw material, the first raw material is cyclocarya paliurus extract, bitter gourd extract, mulberry leaf extract, lutein and pharmaceutic adjuvant, and the pharmaceutic adjuvant is adhesive starch and lubricant magnesium stearate; the second raw material comprises corn starch, pectin and gelatin; the health-care tea comprises, by weight, 40 parts of cyclocarya paliurus extract, 12 parts of bitter gourd extract, 15 parts of mulberry leaf extract, 2.5 parts of lutein, 1.6 parts of corn starch, 1.4 parts of pectin sugar, 1.3 parts of gelatin, 45 parts of starch and 1 part of magnesium stearate;
the cyclocarya paliurus extract is a cyclocarya paliurus leaf extract and a cyclocarya paliurus root extract, and the weight ratio of the cyclocarya paliurus leaf extract to the cyclocarya paliurus root extract is 1.2-2: 1-1.8; the cyclocarya paliurus extract, the bitter gourd extract and the mulberry leaf extract are dry extracts of water extracts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710802725.6A CN107496510B (en) | 2017-09-07 | 2017-09-07 | Cyclocarya paliurus capsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710802725.6A CN107496510B (en) | 2017-09-07 | 2017-09-07 | Cyclocarya paliurus capsule and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107496510A CN107496510A (en) | 2017-12-22 |
| CN107496510B true CN107496510B (en) | 2021-02-26 |
Family
ID=60695850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710802725.6A Expired - Fee Related CN107496510B (en) | 2017-09-07 | 2017-09-07 | Cyclocarya paliurus capsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107496510B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108310050A (en) * | 2018-03-03 | 2018-07-24 | 广西中医药大学 | Blue or green money willow extract and its preparation and hypoglycemic application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102824640A (en) * | 2012-08-06 | 2012-12-19 | 济南圣泉唐和唐生物科技有限公司 | Capsule shell and preparation method thereof |
| CN104042679A (en) * | 2014-07-08 | 2014-09-17 | 江平凡 | Hypoglycemic product containing cyclocarya paliurus |
-
2017
- 2017-09-07 CN CN201710802725.6A patent/CN107496510B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102824640A (en) * | 2012-08-06 | 2012-12-19 | 济南圣泉唐和唐生物科技有限公司 | Capsule shell and preparation method thereof |
| CN104042679A (en) * | 2014-07-08 | 2014-09-17 | 江平凡 | Hypoglycemic product containing cyclocarya paliurus |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107496510A (en) | 2017-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104739921B (en) | A kind of prescription lozenge and preparation method thereof for alleviating visual fatigue | |
| CN104719899B (en) | Ginseng hypoglycemic soft sweets and preparation method | |
| CN107714794B (en) | Russian extract tablet and preparation method thereof | |
| CN103608024A (en) | Pharmaceutical composition for controlling blood sugar, blood lipid and body weight | |
| CN106723015A (en) | A kind of health food and its preparation technology with antifatigue and anti-oxidation function | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| CN106723029A (en) | A kind of health food and its preparation technology with auxiliary hyperglycemic function | |
| CN107496510B (en) | Cyclocarya paliurus capsule and preparation method thereof | |
| CN104783031B (en) | A kind of protect liver protects brain composition | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN106509894A (en) | Moringa oleifera and pseudo-ginseng buccal tablets and preparation technology thereof | |
| CN100450504C (en) | Medication for treating pharyngitis | |
| CN101564511B (en) | Natural protein product for treating diabetes and manufacture method | |
| CN107582896A (en) | It is a kind of that there is preparation for reducing blood pressure and blood lipoid effect and preparation method thereof | |
| CN100455314C (en) | Medication for treating cough | |
| CN1785053A (en) | Health-care food for relieving-vision fatigue and its prepn. method | |
| CN104056020B (en) | A kind of Chinese medicine composition for treating metabolic syndrome | |
| JP4636475B2 (en) | Antidiabetic | |
| CN108635426A (en) | A kind of Colestid traditional Chinese drug inspissation water-bindered pill and preparation process | |
| CN111803559B (en) | Eggplant peel composition with blood sugar reducing effect and preparation method and application thereof | |
| CN118490654B (en) | Anti-fatigue traditional Chinese medicine lozenge and preparation method thereof | |
| CN102764349B (en) | Application of red onion roots in preparing medicine for protecting gastric mucosa | |
| CN104547294B (en) | Application of callicarpa nudiflora in alcohol-relieving and liver-protecting products and products thereof | |
| CN1872139B (en) | Drop pills for treating bronchitis | |
| CN109938301B (en) | Fermented pomelo peel buccal tablet with blood sugar reducing effect and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210226 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |